Physician profile
Ellen Rakhman
NPI 1215575402
$6,481.19
in general payments reported to CMS, 2019-2025
42 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $347 · 2023: $1,084 · 2024: $2,964 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,604.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,179.84 | 2021-2025 | |
| Novo Nordisk INC | $911.50 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $409.73 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $350.74 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $335.08 | 2021-2025 | |
| Mylan Specialty L.P. | $333.13 | 2023-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $330.58 | 2022-2025 | |
| Amgen INC. | $246.56 | 2023-2025 | Otezla, Repatha, Repatha |
| Mannkind Corporation | $225.28 | 2021-2025 | Afrezza |
| Otsuka America Pharmaceutical, INC. | $214.04 | 2023-2025 | Rexulti, Abilify Maintena |
| Almatica Pharma LLC | $189.20 | 2023-2025 | Loreev Xr, Teriparatide, Gralise |
| Glaxosmithkline, LLC. | $156.17 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.10 | 2023-2025 | Jardiance |
| Seqirus USA INC | $129.08 | 2024-2025 | Flucelvax, Fluad |
| Exact Sciences Corporation | $127.11 | 2023-2025 | Cologuard Collection Kit |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $113.27 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $111.12 | 2024-2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $99.41 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $68.13 | 2024-2025 | |
| Ardelyx, INC. | $62.76 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $61.40 | 2023-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Dexcom, INC. | $57.54 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $53.54 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $50.18 | 2024 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $48.92 | 2021-2023 | Trintellix |
| Viatris Specialty LLC | $48.37 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.85 | 2022-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $41.50 | 2023 | Gemtesa |
| Genentech USA, INC. | $38.39 | 2021 | |
| Baxter Healthcare | $36.18 | 2024 | Biopharma Sol - Contract Manuf |
| Phadia US INC. | $35.54 | 2023-2024 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $34.18 | 2025 | Austedo Xr |
| Corcept Therapeutics | $26.30 | 2025 | Korlym |
| Verona Pharma, INC. | $25.23 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $25.00 | 2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $24.61 | 2023 | Strensiq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.93 | 2025 | Caplyta |
| Hologic Sales and Service, LLC | $20.87 | 2023 | Aptima |
| Xeris Pharmaceuticals, INC. | $18.93 | 2025 | Gvoke Hypopen |
| Vbi Vaccine (Delaware) INC. | $17.31 | 2022 | |
| Shield Therapeutics INC | $14.40 | 2023 | Accrufer |
| Theracosbio, LLC | $11.19 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Rakhman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.